Sugi Predict

Sugi Predict / Compounds / SCHEMBL2924367

SCHEMBL2924367

SCHEMBL2924367

COC(=O)c1cc(N)cc2[nH]ncc12

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 1/20 0.55
▸ GAA P10253 3/20 0.41
▸ TDO2 P48775 3/20 0.40
▸ ALDH1A1 P00352 6/20 0.40
▸ KDM4E B2RXH2 4/20 0.40
▸ GLA P06280 2/20 0.40
▸ MAPT P10636 5/20 0.39
▸ IDO1 P14902 1/20 0.38
▸ NQO2 P16083 3/20 0.38
▸ MEN1 O00255 4/20 0.38
▸ KMT2A Q03164 4/20 0.38
▸ POLB P06746 2/20 0.38
▸ HSD17B10 Q99714 2/20 0.37
▸ HPGD P15428 1/20 0.37
▸ CASP1 P29466 1/20 0.37
▸ CASP7 P55210 1/20 0.37
▸ ATM Q13315 1/20 0.37
▸ HTT P42858 2/20 0.37
▸ NPC1 O15118 2/20 0.37
▸ RAB9A P51151 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25996747 0.83 IDO1 (0.49) TSHRTDO2ALDH1A1MAPTIDO1
SCHEMBL459193 0.82 TDO2 (0.53) TSHRTDO2MAPTIDO1
SCHEMBL31158048 0.82 TDO2 (0.53) TSHRTDO2MAPTIDO1
SCHEMBL2592578 0.82 NR4A2 (0.48) TSHRALDH1A1KDM4EMAPTIDO1
SCHEMBL4717977 0.82 TSHR (0.47) TSHR
SCHEMBL5437444 0.78 METAP2 (0.52) TSHRTDO2IDO1CFTR
SCHEMBL2594220 0.77 NOS1 (0.44) TSHRTDO2ALDH1A1MAPTIDO1
SCHEMBL3949930 0.77 PIK3CD (0.53) TSHRGAAKDM4EMAPTIDO1
SCHEMBL31179362 0.76 TSHR (0.51) TSHRGAATDO2ALDH1A1KDM4E
SCHEMBL28265797 0.76 TSHR (0.42) TSHRGAATDO2ALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12606544-B2 JAK1 selective kinase inhibitor DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) 2026-04-21 — — US disclosed
EP-3956322-B1 JAK1 SELECTIVE KINASE INHIBITOR DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) 2025-05-14 — — EP disclosed
US-20250049806-A1 PHARMACEUTICAL COMPOSITION FOR PROVIDING TREATMENT FOR OR PREVENTING ALPORT SYNDROME UBE CORP (JP) 2025-02-13 — — US disclosed
EP-4431098-A1 PHARMACEUTICAL COMPOSITION FOR PROVIDING TREATMENT FOR OR PREVENTING ALPORT SYNDROME UBE Corporation (JP) 2024-09-18 — — EP disclosed
CN-115551846-B 1,4,5, 6-tetrahydropyrimidin-2-amine derivatives ＵＢＥ株式会社 2024-03-08 — — CN disclosed
CN-113710664-B JAK1 selective kinase inhibitors 迪哲(江苏)医药股份有限公司 2024-01-26 — — CN disclosed
US-20230192661-A1 1, 4, 5, 6-TETRAHYDROPYRIMIDINE-2-AMINE DERIVATIVE UBE CORPORATION (JP) 2023-06-22 — — US disclosed
WO-2023085396-A1 PHARMACEUTICAL COMPOSITION FOR PROVIDING TREATMENT FOR OR PREVENTING ALPORT SYNDROME ＵＢＥ株式会社 2023-05-19 — — WO disclosed
EP-4151632-A1 1, 4, 5, 6-TETRAHYDROPYRIMIDINE-2-AMINE DERIVATIVE UBE Corporation (JP) 2023-03-22 — — EP disclosed
CN-115551846-A 1,4,5,6-tetrahydropyrimidin-2-amine derivatives ＵＢＥ株式会社 2022-12-30 — — CN disclosed
EP-3956322-A1 JAK1 SELECTIVE KINASE INHIBITOR DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) 2022-02-23 — — EP disclosed
WO-2020211839-A1 JAK1 SELECTIVE KINASE INHIBITOR DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) 2020-10-22 — — WO disclosed
WO-2020211839-A1 JAK1 SELECTIVE KINASE INHIBITOR DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) 2020-10-22 — — WO disclosed
US-20160272617-A1 SUBSTITUTED PHENYLALANINE DERIVATIVES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2016-09-22 — — US disclosed
US-20100311965-A1 2-AMINOQUINAZOLINE DERIVATIVE CARNA BIOSCIENCES INC. (JP) 2010-12-09 — — US disclosed
US-20100311965-A1 2-AMINOQUINAZOLINE DERIVATIVE CARNA BIOSCIENCES INC. (JP) 2010-12-09 — — US disclosed
US-20100311965-A1 2-AMINOQUINAZOLINE DERIVATIVE CARNA BIOSCIENCES INC. (JP) 2010-12-09 — — US disclosed
EP-2226315-A1 2-AMINOQUINAZOLINE DERIVATIVE Carna Biosciences Inc. (JP) 2010-09-08 — — EP disclosed
EP-2226315-A1 2-AMINOQUINAZOLINE DERIVATIVE Carna Biosciences Inc. (JP) 2010-09-08 — — EP disclosed
WO-2009084695-A1 2-AMINOQUINAZOLINE DERIVATIVE CARNA BIOSCIENCES INC. (JP) 2009-07-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230192661-A1 1, 4, 5, 6-TETRAHYDROPYRIMIDINE-2-AMINE DERIVATIVE DHFR, DPYD, CYP2D6 TSHR 288/4885GAA 3490/4885TDO2 248/4885
US-20160272617-A1 SUBSTITUTED PHENYLALANINE DERIVATIVES PAH, PEPD, AADAT TSHR 2583/4885GAA 643/4885TDO2 100/4885
US-20100311965-A1 2-AMINOQUINAZOLINE DERIVATIVE DSTYK, ABL1, EEF2K TSHR 1995/4885GAA 4374/4885TDO2 2884/4885
US-12606544-B2 JAK1 selective kinase inhibitor JAK1, JAK2, JAK3 TSHR 767/4885GAA 4701/4885TDO2 2741/4885
US-20250049806-A1 PHARMACEUTICAL COMPOSITION FOR PROVIDING TREATMENT FOR OR PREVENTING ALPORT SYNDROME CYP21A2, HSD11B2, MC2R TSHR 1212/4885GAA 1320/4885TDO2 3118/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.